0001237899-18-000016.txt : 20180928 0001237899-18-000016.hdr.sgml : 20180928 20180928163554 ACCESSION NUMBER: 0001237899-18-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180927 FILED AS OF DATE: 20180928 DATE AS OF CHANGE: 20180928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BROWN MICHAEL S CENTRAL INDEX KEY: 0001174475 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 181094590 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2018-09-27 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001174475 BROWN MICHAEL S 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0 Common Stock 2018-09-27 4 M 0 2000 273.67 A 2000 D Common Stock 2018-09-27 4 S 0 389 390.23 D 1611 D Common Stock 2018-09-27 4 S 0 601 391.38 D 1010 D Common Stock 2018-09-27 4 S 0 410 392.37 D 600 D Common Stock 2018-09-27 4 S 0 300 393.49 D 300 D Common Stock 2018-09-27 4 S 0 40 394.43 D 260 D Common Stock 2018-09-27 4 S 0 260 395.42 D 0 D Common Stock 5000 I by SLAT Common Stock 12349 I by Trust Non-Qualified Stock Option (right to buy) 273.67 2018-09-27 4 M 0 2000 0.0 D 2024-01-02 Common Stock 2000 10750 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 389 shares of Company stock on September 27, 2018 at prices ranging from $390.00 to $390.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Represents volume-weighted average price of sales of 601 shares of Company stock on September 27, 2018 at prices ranging from $391.00 to $391.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Represents volume-weighted average price of sales of 410 shares of Company stock on September 27, 2018 at prices ranging from $392.00 to $392.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Represents volume-weighted average price of sales of 300 shares of Company stock on September 27, 2018 at prices ranging from $393.41 to $393.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Represents volume-weighted average price of sales of 260 shares of Company stock on September 27, 2018 at prices ranging from $395.18 to $395.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. /s/**Michael S. Brown 2018-09-28